A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over ...

The FDA granted breakthrough therapy designation to efimosfermin — an investigational, once-monthly fibroblast growth factor ...

GSK reports on a US court ruling in ongoing litigation, AstraZeneca announces US approval for a self-administered lupus treatment, while Harworth Group receives planning consent for a data centre ...

Zaven Boyrazian explains why retail investors are rushing to buy this FTSE 100 pharmaceutical giant and explores whether now's the time to buy. The post UK investors are piling into GSK! Should I buy ...

GSK PLC on Monday announced two positive regulatory rulings for efimosfermin, a once-monthly investigational liver therapy.

Off Shifts Pipeline To First Tracks Biotherapeutics GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties AnaptysBio ...

Moreover, it requires quick strategic thinking and often agile investment attitudes." The transformation of pharmaceutical ...

For Western pharmaceutical leaders, the question is no longer whether to engage Asia, but how to integrate its capabilities ...

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

Cambridge's Nobel Laureate Sir Greg Winter is championing a new global award designed to recognise outstanding science and ...

A new therapy has the potential to cure hundreds of diseases — and even reverse aging. Credit...Photo illustration by Kensuke ...